First dose administered in phase 1/2 clinical trial of OCU410, an emerging therapy for dry AMD

Biotech company Ocugen has started the ArMaDa Phase 1/2 clinical trial of OCU410, a modfier gene therapy product candidate being developed for dry age-related macular degeneration.